title: Serum carbohydrate antigen elevations in endometrial adenocarcinomas: characterization of DU-PAN-2 expression as a tumor marker.
abstract: OBJECTIVE
  To characterize serum elevations of carbohydrate antigens; DU-PAN-2, CA19-9, sialyl Lewisx and CA125 in endometrial adenocarcinomas (EMACs), particularly focusing on the clarification of DU-PAN-2 expression profiles.
  
  
  METHODS
  Sixty-four resected EMACs of endometrioid type were used. The preoperative serum values of four markers were measured and comparatively analyzed regarding the relationship between histological grade and clinicopathological stage.
  
  
  RESULTS
  The overall ratios of positive cases were 26.2% for DU-PAN-2, 25.0% for CA19-9, 13.6% for sialyl Lewisx, and 35.5% for CA125. DU-PAN-2 decreased as the grading went up (G1: 410.3 +/- 243.8 to G3: 246.7 +/- 90.0 U/mL), however, the reverse was true with CA19-9 (G1: 123.9 +/- 147.4 to G3: 320.0 +/- 180.0 U/mL). Sialyl Lewisx showed a strong tendency towards high elevation in G1 (346.3 +/- 102.6 U/mL), compared to G3 (< 2.5 U/mL). CA125 increased markedly as the grading went up (G1: 43.5 +/- 6.3 to G3: 578.0 +/- 10.0 U/mL). During staging-up from I + II to III + IV, the positive ratios inclined in all four markers as follows: DU-PAN-2, 18.4-53.3%; CA19-9, 20.4-40.0%; sialyl Lewisx, 11.4-22.2%; CA125, 31.8-44.4%. Serum elevations and positive ratios were correlated for DU-PAN-2, CA19-9 and CA125, while the reverse relationship was found for sialyl Lewisx.
  
  
  CONCLUSIONS
  It is suggested that DU-PAN-2 tends to be produced more in well-differentiated components of EMACs than in poorly differentiated ones. Since approximately half the cases with EMAC were serologically positive for DU-PAN-2 in stage III + IV, the marker is believed to be of much use for monitoring the cases with an extrauterine extent.
authors.affiliation: Department of Pathology, School of Medicine, Tokai University, Kanagawa, Japan. m-yasuda@is.icc.u-tokai.ac.jp
authors.forename: Masanori
authors.initials: M
authors.lastname: Yasuda
authors.forename: Kaoru
authors.initials: K
authors.lastname: Saito
authors.forename: Youichi
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Toshinari
authors.initials: T
authors.lastname: Muramatsu
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Miyamoto
authors.forename: Masaru
authors.initials: M
authors.lastname: Murakami
authors.forename: Takao
authors.initials: T
authors.lastname: Shinozuka
authors.forename: Bunpei
authors.initials: B
authors.lastname: Ishizuka
authors.forename: Tsunehisa
authors.initials: T
authors.lastname: Makino
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kajiwara
authors.forename: Robert Yoshiyuki
authors.initials: RY
authors.lastname: Osamura
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000276:immunology*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000096:biosynthesis* / Q000097:blood; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000096:biosynthesis* / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood / Q000276:immunology*; D018394:CA-125 Antigen / Q000097:blood / Q000276:immunology; D018395:CA-19-9 Antigen / Q000097:blood / Q000276:immunology; D016889:Endometrial Neoplasms / Q000097:blood / Q000276:immunology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009844:Oligosaccharides / Q000097:blood / Q000276:immunology; D000080506:Sialyl Lewis X Antigen
chemical_list: D000951:Antigens, Neoplasm; D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D018395:CA-19-9 Antigen; C042317:DU-PAN-2 antigen, human; D009844:Oligosaccharides; D000080506:Sialyl Lewis X Antigen